Spinal Muscular Atrophy Treatment Market: Information by SMA Type (Severe, Mild), Treatment (Gene Therapy, Drugs), Route of Administration (Oral, Intrathecal), and Region — Forecast till 2029

Request Free Sample Report

Table Of Content

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Spinal Muscular Atrophy (SMA) Treatment Market

3.3       Key Market Trends

3.3.1   Drivers

3.3.2   Restraints

3.3.3   Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1   Bargaining Power of Suppliers

3.4.2   Bargaining Power of Buyers

3.4.3   Threat of Substitution

3.4.4   Threat of New Entrants

3.4.5   Competitive Rivalry

3.5       Market Share Analysis

4          By SMA Type Overview

4.1       Introduction

4.1.1   Market Size & Forecast (Value)

4.2       Severe

4.2.1   Market Size & Forecast (Value)

4.3       Intermediate

4.3.1   Market Size & Forecast (Value)

5          By Treatment Overview

5.1       Introduction

5.1.1   Market Size & Forecast (Value)

5.2       Gene Therapy

5.2.1   Market Size & Forecast (Value)

5.3       Drugs

5.3.1   Market Size & Forecast (Value)

6          Regional Overview

6.1      Introduction

6.1.1   Market Size & Forecast (Value)

6.2      America

6.2.1   North America

6.2.1.1 U.S.

6.2.1.1.1         By SMA Type

6.2.1.1.2         By Treatment

6.2.1.2 Canada

6.2.1.2.1         By SMA Type

6.2.1.2.2         By Treatment

6.2.1.3 Mexico

6.2.1.3.1         By SMA Type

6.2.1.3.2         By Treatment

6.2.2   Latin America

6.2.2.1            By SMA Type

6.2.2.2            By Treatment

6.3      Europe

6.3.1   Market Size & Forecast (Value)

6.3.2   Western Europe

6.3.2.1 Germany

6.3.2.1.1         By SMA Type

6.3.2.1.2         By Treatment

6.3.2.2 France

6.3.2.2.1         By SMA Type

6.3.2.2.2         By Treatment

6.3.2.3 U.K

6.3.2.3.1         By SMA Type

6.3.2.3.2         By Treatment

6.3.2.4 Italy

6.3.2.4.1         By SMA Type

6.3.2.4.2         By Treatment

6.3.2.5 Spain

6.3.2.5.1         By SMA Type

6.3.2.5.2         By Treatment

6.3.3   Western Europe

6.3.3.1            By SMA Type

6.3.3.2            By Treatment

6.3.4   Rest of Europe

6.3.4.1            By SMA Type

6.3.4.2            By Treatment

6.4      Asia Pacific

6.4.1   Market Size & Forecast (Value)

6.4.2   Japan

6.4.2.1            By SMA Type

6.4.2.2            By Treatment

6.4.3   China

6.4.3.1            By SMA Type

6.4.3.2            By Treatment

6.4.4   Australia

6.4.4.1            By SMA Type

6.4.4.2            By Treatment

6.4.5   India

6.4.5.1            By SMA Type

6.4.5.2            By Treatment

6.4.6   South Korea

6.4.6.1            By SMA Type

6.4.6.2            By Treatment

6.4.7   Rest of Asia-Pacific

6.4.7.1            By SMA Type

6.4.7.2            By Treatment

6.5      Middle East & Africa

6.5.1   Market Size & Forecast (Value)

6.5.2   Saudi Arabia

6.5.2.1            By SMA Type

6.5.2.2            By Treatment

6.5.3   South Africa

6.5.3.1            By SMA Type

6.5.3.2            By Treatment

6.5.4   Kuwait

6.5.4.1            By SMA Type

6.5.4.2            By Treatment

6.5.5   Rest of Middle East & Africa

6.5.5.1            By SMA Type

6.5.5.2            By Treatment

7          Company Profile

7.1      Pfizer Inc.

7.1.1   Company Overview

7.1.2   Financial Performance

7.1.3   Recent Developments

7.1.4   Product Portfolio

7.2      Biogen Idec

7.2.1   Company Overview

7.2.2   Financial Performance

7.2.3   Recent Developments

7.2.4   Product Portfolio

7.3      Boehringer Ingelheim GmbH

7.3.1   Company Overview

7.3.2   Financial Performance

7.3.3   Recent Developments

7.3.4   Product Portfolio

7.4      Ionis Pharmaceuticals, Inc.

7.4.1   Company Overview

7.4.2   Financial Performance

7.4.3   Recent Developments

7.4.4   Product Portfolio

7.5      Avexis, Inc.

7.5.1   Company Overview

7.5.2   Financial Performance

7.5.3   Recent Developments

7.5.4   Product Portfolio

7.6      Novartis AG

7.6.1   Company Overview

7.6.2   Financial Performance

7.6.3   Recent Developments

7.6.4   Product Portfolio

7.7      Cytokinetics, Inc.

7.7.1   Company Overview

7.7.2   Financial Performance

7.7.3   Recent Developments

7.7.4   Product Portfolio

7.8      F. Hoffmann-La Roche AG

7.8.1   Company Overview

7.8.2   Financial Performance

7.8.3   Recent Developments

7.8.4   Product Portfolio

7.9      Regeneron Pharmaceuticals, Inc.

7.9.1   Company Overview

7.9.2   Financial Performance

7.9.3   Recent Developments

7.9.4   Product Portfolio

Report Description Download Sample

Copyright . All rights Reserved By Straits Research